Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 82 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2014', provides an overview of the Hospital Acquired Pneumonia (HAP)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hospital Acquired Pneumonia (HAP), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hospital Acquired Pneumonia (HAP) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Hospital Acquired Pneumonia (HAP) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Hospital Acquired Pneumonia (HAP) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hospital Acquired Pneumonia (HAP) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hospital Acquired Pneumonia (HAP)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Hospital Acquired Pneumonia (HAP) Overview 7
Therapeutics Development 8
Pipeline Products for Hospital Acquired Pneumonia (HAP) - Overview 8
Pipeline Products for Hospital Acquired Pneumonia (HAP) - Comparative Analysis 9
Hospital Acquired Pneumonia (HAP) - Therapeutics under Development by Companies 10
Hospital Acquired Pneumonia (HAP) - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Hospital Acquired Pneumonia (HAP) - Products under Development by Companies 14
Hospital Acquired Pneumonia (HAP) - Companies Involved in Therapeutics Development 15
Achaogen Inc. 15
Adenium Biotech ApS 16
AstraZeneca PLC 17
Cubist Pharmaceuticals, Inc. 18
Dong-A Socio Group 19
MedImmune, LLC 20
Meiji Seika Pharma Co., Ltd. 21
Melinta Therapeutics, Inc 22
Nabriva Therapeutics AG 23
Tetraphase Pharmaceuticals Inc. 24
Hospital Acquired Pneumonia (HAP) - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Combination Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
(ceftazidime + avibactam) - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
(ceftolozane + tazobactam) - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
AA-139 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
arbekacin - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
BC-3781 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
delafloxacin - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
eravacycline - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
MEDI-3902 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
plazomicin sulfate - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
tedizolid phosphate - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Hospital Acquired Pneumonia (HAP) - Recent Pipeline Updates 55
Hospital Acquired Pneumonia (HAP) - Dormant Projects 74
Hospital Acquired Pneumonia (HAP) - Discontinued Products 75
Hospital Acquired Pneumonia (HAP) - Product Development Milestones 76
Featured News & Press Releases 76
Oct 03, 2013: Tetraphase to Present New Data at IDWeek on Eravacycline's Potential Activity in Treating Serious Respiratory Infections 76
Sep 06, 2013: Trius Therapeutics to Present Data From Antibiotics Development Programs at ICAAC 2013 76
May 07, 2013: Cubist's Late-stage Antibiotic Candidate CXA-201 Receives FDA Fast Track Designation 78
Jan 07, 2013: Trius Therapeutics's Tedizolid Receives Qualified Infectious Disease Product Designation From FDA 79
Dec 06, 2012: Cubist Pharma's Antibiotic Candidate Ceftolozane Obtains QIDP Designation From FDA 79
Appendix 81
Methodology 81
Coverage 81
Secondary Research 81
Primary Research 81
Expert Panel Validation 81
Contact Us 82
Disclaimer 82

List of Tables
Number of Products under Development for Hospital Acquired Pneumonia (HAP), H2 2014 8
Number of Products under Development for Hospital Acquired Pneumonia (HAP) - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Hospital Acquired Pneumonia (HAP) - Pipeline by Achaogen Inc., H2 2014 15
Hospital Acquired Pneumonia (HAP) - Pipeline by Adenium Biotech ApS, H2 2014 16
Hospital Acquired Pneumonia (HAP) - Pipeline by AstraZeneca PLC, H2 2014 17
Hospital Acquired Pneumonia (HAP) - Pipeline by Cubist Pharmaceuticals, Inc., H2 2014 18
Hospital Acquired Pneumonia (HAP) - Pipeline by Dong-A Socio Group, H2 2014 19
Hospital Acquired Pneumonia (HAP) - Pipeline by MedImmune, LLC, H2 2014 20
Hospital Acquired Pneumonia (HAP) - Pipeline by Meiji Seika Pharma Co., Ltd., H2 2014 21
Hospital Acquired Pneumonia (HAP) - Pipeline by Melinta Therapeutics, Inc, H2 2014 22
Hospital Acquired Pneumonia (HAP) - Pipeline by Nabriva Therapeutics AG, H2 2014 23
Hospital Acquired Pneumonia (HAP) - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2014 24
Assessment by Monotherapy Products, H2 2014 25
Assessment by Combination Products, H2 2014 26
Number of Products by Stage and Target, H2 2014 28
Number of Products by Stage and Mechanism of Action, H2 2014 30
Number of Products by Stage and Route of Administration, H2 2014 32
Number of Products by Stage and Molecule Type, H2 2014 34
Hospital Acquired Pneumonia (HAP) Therapeutics - Recent Pipeline Updates, H2 2014 55
Hospital Acquired Pneumonia (HAP) - Dormant Projects, H2 2014 74
Hospital Acquired Pneumonia (HAP) - Discontinued Products, H2 2014 75